Cancer cell membrane-camouflaged paclitaxel/PLGA nanoparticles for targeted therapy against lung cancer

• DOI: 10.1016/j.biopha.2024.117102
• Publication Date: 2024-07-10T07:07:21Z
• Authors: Jiahan Zhou; Shengli Wan; Yuesong Wu; Haiyang Hu; Yang Liu; Zuyue Liao; Mengyao Xu; Jianming Wu; Qingze Fan
• Keywords: 0301 basic medicine; Mice, Inbred BALB C; Drug Carriers; Lung Neoplasms; Paclitaxel; Cell Membrane; Mice, Nude; Antineoplastic Agents, Phytogenic; Xenograft Model Antitumor Assays; Mice; 03 medical and health sciences; Polylactic Acid-Polyglycolic Acid Copolymer; A549 Cells; Humans; Animals; Nanoparticles

Paclitaxel (PTX) is a first-line drug for the treatment of lung cancer, but its targeting and therapeutic effect are unsatisfactory. Herein, lung cancer cell (A549) membrane biomimetic PTX-loaded poly (lactic-co-glycolic acid) (PLGA) nanoparticles (AM@PTX-NPs) were constructed to eliminate the shortcomings of PTX. The AM@PTX-NPs were successfully prepared with a high drug loading efficiency (10.90±0.06 %). Moreover, transmission electron microscopy, SDS-PAGE, and western blotting proved that AM@PTX-NPs were spherical nanoparticles camouflaged by the A549 cell membrane. Both in vitro and in vivo assays revealed that the AM@PTX-NPs displayed outstanding targeting capacity due to A549 membrane modification. The cytotoxicity experiment showed that the developed biomimetic formulation was able to effectively reduce the proliferation of A549 cells. Moreover, AM@PTX-NPs exhibited a significant tumor growth inhibition rate (73.00 %) with good safety in the tumor-bearing mice, which was higher than that of the PTX-NPs without A549 membrane coating (37.39 %). Overall, the constructed bioinspired vector could provide a novel platform for the PTX delivery and demonstrated a promising strategy for the targeted cancer treatment.